{"id":"hpv-mmr-0d-hpv-6m","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain, swelling, or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia or arthralgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The regimen administers an HPV vaccine at baseline (day 0) simultaneously with MMR vaccine, followed by a second HPV vaccine dose at 6 months. HPV vaccine stimulates antibody production against HPV capsid proteins to prevent cervical and other HPV-related cancers, while MMR vaccine provides live attenuated viral immunity against measles, mumps, and rubella. The staggered HPV dosing allows for optimal antibody titers while MMR provides concurrent protection against three viral diseases.","oneSentence":"This is a sequential immunization regimen combining HPV and MMR vaccines to provide protection against human papillomavirus and measles, mumps, and rubella through adaptive immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:31:45.665Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of human papillomavirus-related cancers and precancerous lesions"},{"name":"Prevention of measles, mumps, and rubella"}]},"trialDetails":[{"nctId":"NCT05279248","phase":"PHASE4","title":"The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2021-08-25","conditions":"Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"HPV+MMR（0d），HPV（6m）","genericName":"HPV+MMR（0d），HPV（6m）","companyName":"Zhejiang Provincial Center for Disease Control and Prevention","companyId":"zhejiang-provincial-center-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"This is a sequential immunization regimen combining HPV and MMR vaccines to provide protection against human papillomavirus and measles, mumps, and rubella through adaptive immune response. Used for Prevention of human papillomavirus-related cancers and precancerous lesions, Prevention of measles, mumps, and rubella.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}